Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity
Wang, Q.; Michailidis, E.; Yu, Y.; Wang, Z.; Hurley, A. M.; Oren, D. A.; Mayer, C. T.; Gazumyan, A.; Liu, Z.; Zhou, Y.; Schoofs, T.; Yao, K.-h.; Nieke, J.; Wu, J.; Jiang, Q.; Zou, C.; Kabbani, M.; Quirk, C.; Oliveira, T.; Chhosphel, K.; Zhang, Q.; Schneider, W. M.; Jahan, C.; Ying, T.; Horowitz, J.; Caskey, M.; Jankovic, M.; Robbiani, D. F.; Wen, Y.; de Jong, Y. P.; Rice, C. M.; Nussenzweig, M. C.
Show abstract
SUMMARYAlthough there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protective and constitute clinical correlates of recovery from infection. To examine the human neutralizing antibody response to HBV in elite neutralizers we screened 144 individuals. The top individuals produced shared clones of broadly neutralizing antibodies (bNAbs) that targeted 3 non-overlapping epitopes on the HBV S antigen (HBsAg). Single bNAbs protected humanized mice against infection, but selected for resistance mutations in mice with established infection. In contrast, infection was controlled by a combination of bNAbs targeting non-overlapping epitopes with complementary sensitivity to mutations that commonly emerge during human infection. The co-crystal structure of one of the bNAbs with a peptide epitope containing residues frequently mutated in human immune escape variants revealed a loop anchored by oppositely charged residues. The structure provides a molecular explanation for why immunotherapy for HBV infection may require combinations of complementary bNAbs.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses 96%
- A genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production 96%
- Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques 96%
Similar papers in this journal
- Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics 96%
- Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 95%
- SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated nef variant 95%
Similar papers in this journal
- A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus 95%
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 94%
- Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.